Darolutamide clinical trials
Also written Nubeqa, ODM-201 and BAY 1841788.
How each study uses darolutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the darolutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Jul 2019 · NUBEQA · NDA 212099 (FDA, Drugs@FDA)
- European Union
- 27 Mar 2020 · Nubeqa · EMEA/H/C/004790 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
76 studies that test it; most in 2026 (11); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 10 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 9 |
| 2025 | 5 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 51
Bayer (16) · Orion Corporation, Orion Pharma (4) · UNICANCER (3) · National Cancer Institute (NCI) (2) · ECOG-ACRIN Cancer Research Group (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Peking University First Hospital (2) · AdventHealth (1)
Often tested with
Tested in the same studies.
Leuprolide (5) · Enzalutamide (5) · Docetaxel (4) · Antiandrogens (4) · Abiraterone (4) · Relugolix (3) · Degarelix (3) · Bicalutamide (2)
Related medicines
As reviewed, each with the page that says it.
- One of Antiandrogens source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 11, 3 in phase 3
Studies that test darolutamide, phase 3 first.
- Nov 2026Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPhase 3 · NRG Oncology
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Jul 2027A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesPhase 3 · Bayer
- Nov 2026Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerPhase 2 · University of California, Davis
- Nov 2026Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersPhase 2 · National Cancer Institute (NCI)
- Dec 2026COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcerPhase 4 · Brazilian Clinical Research Institute
- May 2027Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPCPhase 2 · Erasmus Medical Center
- Jun 2027Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScorePhase 2 · Region Stockholm
- Jul 2027177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical TrialPhase 4 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Sep 2027A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)Phase 1 · K36 Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses darolutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 77
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07190300Written as Darolutamide
- A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)RecruitingPhase 4BayerNCT05348876Written as Darolutamide (Nubeqa, BAY1841788)
- A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.RecruitingPhase 2BayerNCT07450599Written as Darolutamide
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)RecruitingPhase 1K36 Therapeutics, Inc.NCT07103018Written as KTX-2001 + Darolutamide (NUBEQA®)
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingPhase 2Swiss Cancer InstituteNCT06401980Written as Darolutamide
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07027124Written as Darolutamide
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07852195Written as Darolutamide
- Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPCRecruitingPhase 2Erasmus Medical CenterNCT05762536Written as Darolutamide
- Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPCRecruitingPhase 2Yonghong LiNCT07503379Written as Darolutamide + ADT Combined with Low-dose Docetaxel
- Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseRecruitingPhase 3UNICANCERNCT06625970Written as Darolutamide
- Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.Not yet recruitingPhase 2RenJi HospitalNCT07730151Written as Darolutamide
- 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical TrialNot yet recruitingPhase 4The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07677566Written as Darolutamide combined with 177Lu-PSMA-617
- SNV1521 in Participants With Advanced Solid TumorsRecruitingPhase 1Synnovation Therapeutics, Inc.NCT06220864Written as Darolutamide
- Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScoreRecruitingPhase 2Region StockholmNCT07617272Written as Darolutamide
- ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)RecruitingPhase 3UNICANCERNCT04916613Written as Darolutamide 300 mg
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1/2Celcuity IncNCT06190899Written as Darolutamide
- Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical StudyNot yet recruitingEarly Phase 1Zhongda HospitalNCT07516704Written as Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingPhase 2/3Cancer Research AntwerpNCT06282588Written as Darolutamide
- Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate CancerNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07476677Written as Darolutamide
- Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerRecruitingPhase 2University of California, DavisNCT06173362Written as Darolutamide
See all 77 studies that test darolutamide →
Given beside what is tested · 22 — darolutamide is usual care or a partner of the new treatment
- EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsRecruitingPhase 1/2Eisbach Bio GmbHNCT06525298Written as Darolutamide (BAY 1841788)
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Darolutamide
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)RecruitingPhase 3ORIC PharmaceuticalsNCT07723248Written as Darolutamide
- Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)RecruitingPhase 1Janux TherapeuticsNCT05519449Written as Darolutamide
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Daiichi SankyoNCT07244341Written as Darolutamide
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as Darolutamide
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3AstraZenecaNCT07711002Written as Darolutamide
- Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug InteractionRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07620041Written as Darolutamide
- PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPCNot yet recruitingPhase 2West China HospitalNCT07649421Written as Darolutamide 600 mg twice daily
- A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPCRecruitingPhase 1/2Pathos AI, Inc.NCT06785636Written as Pocenbrodib and Darolutamide
- Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate CancerNot yet recruitingPhase 2Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDNCT07717099Written as Darolutamide Oral Tablet
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseRecruitingPhase 3Canadian Cancer Trials GroupNCT06592924Written as Darolutamide (BAY 1841788)
- Study of ORIC-944 in Patients With Metastatic Prostate CancerRecruitingPhase 1ORIC PharmaceuticalsNCT05413421Written as Darolutamide (Nubeqa®) 300 mg tablets
- Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional ImagingRecruitingPhase 3UNICANCERNCT06276465Written as Darolutamide 300 mg
- Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerActive, not recruitingPhase 1AmgenNCT07140900Written as Darolutamide
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsActive, not recruitingPhase 3AstraZenecaNCT06120491Written as Darolutamide
- Study to Evaluate CCS1477 in Advanced TumoursCompletedPhase 1/2CellCentric Ltd.NCT03568656Written as Darolutamide
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerActive, not recruitingPhase 1/2AstraZenecaNCT05367440Written as Darolutamide
- Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate CancerCompletedPhase 2BayerNCT05171387Written as Darolutamide 600 mg twice daily
- Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate CancerCompletedPhase 1BayerNCT03724747Written as Darolutamide(BAY1841788)
Showing 20 of 22.
As the comparator · 2 — what is tested is compared with darolutamide
- Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingPhase 2TransThera Sciences (Nanjing), Inc.NCT07871110Written as Darolutamide 600 mg twice daily
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Darolutamide
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call darolutamide · ClinicalTrials.gg INT000459
- MeSH (NLM) C000607739darolutamideOne source ClinicalTrials.gov
- UNII (FDA) X05U0N2RCODAROLUTAMIDEConfirmed FDA, Wikidata
- RxNorm 2180325Confirmed FDA, Wikidata
- Wikidata Q25091391darolutamideConfirmed FDA, Wikidata
- NCI Thesaurus C104748DarolutamideOne source FDA
- DrugBank DB12941One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607739 | darolutamide | One source ClinicalTrials.gov |
| UNII (FDA) | X05U0N2RCO | DAROLUTAMIDE | Confirmed FDA, Wikidata |
| RxNorm | 2180325 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25091391 | darolutamide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C104748 | Darolutamide | One source FDA |
| DrugBank | DB12941 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.